Mineralys Therapeutics Announces Expansion Of Planned Phase 2 Trial Of Lorundrostat Alone And In Combination With SGLT2 Inhibitor To Treat Patients With Chronic Kidney Disease
Portfolio Pulse from Benzinga Newsdesk
Mineralys Therapeutics plans to expand its Phase 2 trial of lorundrostat, alone and in combination with an SGLT2 inhibitor, to treat patients with Chronic Kidney Disease (CKD). The trial is set to begin in the second half of 2023. A safety profiling trial for individuals with stage 3b and 4 CKD will run in parallel.
July 17, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The announcement of the expansion of the Phase 2 trial for lorundrostat by Mineralys Therapeutics could potentially boost investor confidence in the company's research and development capabilities.
The expansion of the Phase 2 trial indicates progress in the company's research and development efforts. This could potentially attract more investors, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100